[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA199900575A1 - Композиции на основе слитого белка ов и способы их применения - Google Patents

Композиции на основе слитого белка ов и способы их применения

Info

Publication number
EA199900575A1
EA199900575A1 EA199900575A EA199900575A EA199900575A1 EA 199900575 A1 EA199900575 A1 EA 199900575A1 EA 199900575 A EA199900575 A EA 199900575A EA 199900575 A EA199900575 A EA 199900575A EA 199900575 A1 EA199900575 A1 EA 199900575A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
application
compositions based
fused
protection substance
Prior art date
Application number
EA199900575A
Other languages
English (en)
Other versions
EA004790B1 (ru
Inventor
Майкл Бенджамин Мэнн
Рэнди Айра Хект
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA199900575A1 publication Critical patent/EA199900575A1/ru
Publication of EA004790B1 publication Critical patent/EA004790B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

Настоящее изобретение относится к композициям слитого белка Fc-OB, способам получения таких композиций и их применения. В частности, настоящее изобретение относится к генетически или химически слитому белку, состоящему из Fc района иммуноглобулина, его производного или аналога, слитого с N-терминальной областью белка OB, его производного или аналога.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900575A 1996-12-20 1997-12-11 Композиции на основе слитого белка ов и способы их применения EA004790B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20
PCT/US1997/023183 WO1998028427A1 (en) 1996-12-20 1997-12-11 Ob fusion protein compositions and methods

Publications (2)

Publication Number Publication Date
EA199900575A1 true EA199900575A1 (ru) 2000-02-28
EA004790B1 EA004790B1 (ru) 2004-08-26

Family

ID=25090296

Family Applications (2)

Application Number Title Priority Date Filing Date
EA199900575A EA004790B1 (ru) 1996-12-20 1997-12-11 Композиции на основе слитого белка ов и способы их применения
EA200100216A EA004791B1 (ru) 1996-12-20 1997-12-11 Композиции на основе слитого белка ob и способы их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200100216A EA004791B1 (ru) 1996-12-20 1997-12-11 Композиции на основе слитого белка ob и способы их применения

Country Status (25)

Country Link
EP (2) EP1835030A1 (ru)
JP (2) JP4175668B2 (ru)
KR (1) KR100937550B1 (ru)
CN (1) CN1195858C (ru)
AR (2) AR009436A1 (ru)
AT (1) ATE351910T1 (ru)
AU (1) AU5606098A (ru)
BG (1) BG64288B1 (ru)
BR (1) BR9713755A (ru)
CA (1) CA2275183A1 (ru)
CZ (1) CZ298203B6 (ru)
DE (1) DE69737266T2 (ru)
DK (1) DK0954588T3 (ru)
EA (2) EA004790B1 (ru)
ES (1) ES2280083T3 (ru)
HU (1) HU227088B1 (ru)
IL (1) IL130396A (ru)
NO (2) NO324506B1 (ru)
NZ (1) NZ514145A (ru)
PL (1) PL194159B1 (ru)
PT (1) PT954588E (ru)
RS (1) RS49927B (ru)
SK (1) SK287578B6 (ru)
WO (1) WO1998028427A1 (ru)
ZA (1) ZA9711239B (ru)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ATE455554T1 (de) * 1995-11-22 2010-02-15 Amgen Inc Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
CN1202862C (zh) * 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
AU763719B2 (en) 1997-12-08 2003-07-31 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EP1950223A3 (en) 1998-03-09 2009-05-13 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
KR100827757B1 (ko) 1999-08-09 2008-05-07 메르크 파텐트 게엠베하 복수의 시토킨-항체 복합체
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2001081377A2 (en) * 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
PL362414A1 (en) 2001-02-19 2004-11-02 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
ES2393733T3 (es) 2001-03-07 2012-12-27 Merck Patent Gmbh Tecnología de expresión para proteínas que contienen una fracción de anticuerpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
PL205352B1 (pl) 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
CA2464277C (en) 2001-10-22 2013-02-05 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
BR0214650A (pt) 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1572748B1 (en) 2002-12-17 2010-06-23 MERCK PATENT GmbH Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
ATE393169T1 (de) 2003-12-30 2008-05-15 Merck Patent Gmbh Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
DK2412728T3 (en) 2004-08-03 2015-04-07 Innate Pharma Therapeutic compositions for cancer, that target 4Ig-B7-H3
SI1797127T1 (sl) 2004-09-24 2017-09-29 Amgen Inc. Modificirane fc-molekule
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
KR20070085886A (ko) 2004-12-09 2007-08-27 메르크 파텐트 게엠베하 감소된 면역원성의 ｉｌ-7 변이체
EA014647B1 (ru) * 2005-08-11 2010-12-30 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
CA2624893C (en) 2005-10-21 2015-03-17 Erhard Kopetzki Method for the recombinant expression of a polypeptide
EP1991577A2 (en) 2006-01-31 2008-11-19 Parkinson, John F. Modulation of mdl-1 activity for treatment of inflammatory disease
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
DK2621515T3 (en) 2010-09-28 2017-07-17 Aegerion Pharmaceuticals Inc Chimeric seal-human leptin polypeptide with increased solubility
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
KR102067635B1 (ko) 2011-10-05 2020-01-17 원드 매터리얼 엘엘씨 리튬 이온 배터리용 실리콘 나노구조체 활물질, 및 그에 관련된 공정, 조성물, 구성요소 및 디바이스
RS58010B1 (sr) 2012-09-27 2019-02-28 Childrens Medical Ct Corp Jedinjenja za lečenje gojaznosti i postupci za njihovu upotrebu
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
WO2015153933A1 (en) 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP4283304A3 (en) 2016-09-12 2024-02-28 Amryt Pharmaceuticals Inc. Methods of detecting anti-leptin neutralizing antibodies
CN110183530A (zh) 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPH10503371A (ja) * 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ATE455554T1 (de) * 1995-11-22 2010-02-15 Amgen Inc Verfahren zur erhöhung der mageren fleischmasse mit fettleibigkeitsprotein (ob) zusammensetzungen
CA2238307A1 (en) * 1995-12-27 1997-07-10 Genentech, Inc. Ob protein derivatives having prolonged half-life

Also Published As

Publication number Publication date
HU227088B1 (en) 2010-06-28
EP1835030A1 (en) 2007-09-19
NO325096B1 (no) 2008-02-04
IL130396A0 (en) 2000-06-01
EA004791B1 (ru) 2004-08-26
AR059907A2 (es) 2008-05-07
CZ9902036A3 (cs) 2000-10-11
DE69737266D1 (de) 2007-03-08
YU27999A (sh) 2000-10-30
BG103522A (en) 2000-03-31
RS49927B (sr) 2008-09-29
ZA9711239B (en) 1998-06-23
JP2008289487A (ja) 2008-12-04
ES2280083T3 (es) 2007-09-01
SK287578B6 (sk) 2011-03-04
HUP0000302A2 (hu) 2000-06-28
PL194159B1 (pl) 2007-05-31
DK0954588T3 (da) 2007-05-14
EA004790B1 (ru) 2004-08-26
AR009436A1 (es) 2000-04-12
CA2275183A1 (en) 1998-07-02
NO324506B1 (no) 2007-11-05
NO20071415L (no) 1999-08-19
KR100937550B1 (ko) 2010-01-19
AU5606098A (en) 1998-07-17
DE69737266T2 (de) 2007-11-08
NO992779L (no) 1999-08-19
WO1998028427A1 (en) 1998-07-02
ATE351910T1 (de) 2007-02-15
HK1021388A1 (en) 2000-06-09
IL130396A (en) 2011-09-27
NZ514145A (en) 2003-08-29
EP0954588B1 (en) 2007-01-17
SK77499A3 (en) 2001-04-09
JP4659068B2 (ja) 2011-03-30
EP0954588A1 (en) 1999-11-10
JP4175668B2 (ja) 2008-11-05
EA200100216A1 (ru) 2001-08-27
PT954588E (pt) 2007-03-30
PL334242A1 (en) 2000-02-14
CN1195858C (zh) 2005-04-06
KR20000069617A (ko) 2000-11-25
NO992779D0 (no) 1999-06-08
BG64288B1 (bg) 2004-08-31
JP2001512417A (ja) 2001-08-21
CZ298203B6 (cs) 2007-07-18
BR9713755A (pt) 2000-02-01
CN1246154A (zh) 2000-03-01
HUP0000302A3 (en) 2005-12-28

Similar Documents

Publication Publication Date Title
EA200100216A1 (ru) Композиции на основе слитого белка ов и способы их применения
IT8367525A0 (it) Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
DE60036552D1 (de) Fc-fusionsproteine zur erhöhung der immunogenität von protein- und peptid-antigenen
DE69535948D1 (de) Von wd-40 abstammende peptide und ihre verwendung
DK1088084T3 (da) Erythropoietin analog-humant serumalbumin fusionsprotein
DK0929564T3 (da) Höjniveau-ekspression af proteiner
DK0539530T3 (da) Rensningsstyret kloning af peptider
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
FI843451A0 (fi) Syntetiska vaermestabila enterotoxin-polypeptider av excherichia coli och multimerer daerav.
CA2124953A1 (en) Peptides related to prion proteins
ATE375365T1 (de) Antikörper varianten und fragmente davon
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
ES2188935T3 (es) Polipeptido de fusion para influir sobre interacciones entre proteinas.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
DK0532587T3 (da) Fremgangsmåder til trans-destabilisering af specifikke proteiner in vivo
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
ATE269406T1 (de) Expression von beta-2-mikroglobulin in pichia pastoris
DE69434384D1 (de) Metalkomplexbildner
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
ES2172044T3 (es) Supresion de la proliferacion de celulas t usando fragmentos peptidicos de proteina basica de mielina.
MX9203138A (es) Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
FI812859A7 (fi) Uudet karboksialkyyli-peptidit ja peptidien tioeetterit ja eetterit verenpainetta alentavina aineina.
PT625157E (pt) Epitopes p1a1 e p1a2 da gpiiia da plaqueta sua preparacao e utilizacao

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU